Younger, Smaller Children Show Less Success With ART
Although the ODYSSEY trial showed superior efficacy of dolutegravir (DTG)-based treatment than standard of care, data on predictors of treatment failure in children starting ART on DTG-based regimens are limited, wrote James Wyncoll, PhD, medical statistician at University College London, London, England, and colleagues in their abstract.
The researchers reviewed data on 381 children who started first-line ART: 189 with DTG and 192 with standard of care. Most of the children (82%) were in Africa, 13% were in Thailand, and 5% were in Europe. At baseline, the median age of the children was 10.5 years, and the median CD4 percentage was 20%. The median BMI-for-age z-score was -0.58, and 19% of the participants met the World Health Organization (WHO) criteria for stage III/IV disease.
The researchers considered the predictive values of baseline characteristics across four domains (anthropometrics, HIV indicators, hematology, and demographics) for treatment failure after 96 weeks.
Overall, 75 children experienced treatment failure by 96 weeks, including 24 in the DTG group and 51 in the standard-of-care group. Fewer children treated with DTG experienced treatment failure and the risk declined with increasing age, the researchers wrote. However, predictors of treatment failure were not significantly different between treatment groups, they said.
In the domain-specific models, after adjustment for weight and trial arm, independent and significant predictors of treatment failure included low BMI-for-age, low CD4%, WHO stage III/IV events, high neutrophils, and care at a location in Africa.
In a multivariate analysis, DTG treatment, lower weight, CD4%, ongoing WHO stage III/IV events, and African region remained as significant predictors of treatment failure ( P < .1). Neutrophils were no longer significant after adjustment for ongoing WHO stage III/IV events, and BMI-for-age was no longer a significant predictor after adjustment for CD4% and region.
'The findings of this study can help clinicians by identifying characteristics at ART initiation which predict a child's risk of treatment failure,' Wyncoll told Medscape Medical News . This study provides information on predictors of treatment failure in children starting ART for the first time, including those starting DTG regimens, he said.
Outside of clinical trials, adolescents receiving ART reportedly fared worse than younger children, but the current study showed that the risk for treatment failure declined with increasing age, Wyncoll said. 'We think it's likely that in trials, where participants have increased support, adolescents have good responses to treatment, and it is the youngest children who are at highest risk of treatment failure,' he noted. Reasons for greater treatment failure in younger children may include the need for different formulations, as well as the reliance on caregivers to administer the drugs, which can be difficult, he added.
Both CD4% and BMI-for-age are previously recognized predictors of treatment failure.
Takeaways and Next Steps
The study's findings support previous research showing young age as a strong risk factor for treatment failure with ART, Wyncoll told Medscape Medical News.
'Even with early diagnosis and ART, other studies like the EARTH cohort and the LIFE trial show high mortality in the first 2 years of life, especially within the first 6 months,' he said. 'The EARTH study found that an adverse maternal social environment was linked to poorer outcomes and higher treatment failure in young children, emphasizing the need for strong, sustained support for mothers during pregnancy and early life of infants, including emotional and adherence support,' he noted. Screening for and preventing opportunistic infections such as tuberculosis and giving nutritional support is essential to promote treatment success, and baseline CD4 percentage can help identify children at highest risk for treatment failure, he said.
The final model in the current study provides the basis for an online risk prediction tool for treatment failure, Wyncoll explained. Clinicians would enter a child's characteristics (such as treatment type, age, CD4%, and BMI for age) at ART initiation.
'Children are currently left behind when we consider novel treatment regimens,' Wyncoll said. 'Our work highlights the need for innovative approaches and more research into improved treatment for vulnerable children, such as different ART delivery methods or enhanced therapeutics,' he added.
Although the researchers concluded that predictors of treatment failure for children in the DTG and SOC groups were the same, the findings were limited by the low rates of treatment failure for the children on DTG, Wyncoll told Medscape Medical News . 'Further research is needed using real-world data from children starting dolutegravir to consolidate these findings,' he said.
Don't Discount DTG for Children
Relatively few studies have examined risk factors for virologic failure in children with HIV, especially those on DTG, said Monica Gandhi, MD, director of the University of California San Francisco (UCSF) Bay Area Center for AIDS Research and professor of medicine at UCSF, in an interview.
The current study findings showing a lower CD4 count when initiating ART or ongoing advanced HIV (as represented by the WHO stage III/IV events) or lower weight when starting ART were all risk factors for failure and were not unexpected, Gandhi told Medscape Medical News . 'What was surprising was to see DTG-based ART more associated with failure than standard-of-care (SoC) ART, since DTG is more potent and durable in adults,' she said.
The clinical takeaway is to try to start ART in children as soon as possible to avoid low CD4 counts or more advanced HIV on ART, both of which are risk factors for failure, Gandhi said. DTG-based ART should still be the standard of care among children, but additional research is need to determine into what kind of formulations work best younger ages, such as a dispersible tablet for oral suspension, she added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Avidity (RNA) Gets 26% Jump on Potential Takeover
We recently published . Avidity Biosciences, Inc. (NASDAQ:RNA) is one of the best-performing stocks on Wednesday. Avidity Biosciences rallied for a third day on Wednesday, jumping 26.14 percent to close at $48.26 as investors gobbled up shares following reports that it received an acquisition bid from Swiss drugmaker Novartis AG (NYSE:NVS). A report by the Financial Times, citing people privy to the matter, said that Novartis AG (NYSE:NVS) offered Avidity Biosciences, Inc. (NASDAQ:RNA) to acquire the company, in line with the former's plans to boost its pipeline of medicines targeting rare genetic disorders. Meanwhile, the report said that Avidity Biosciences, Inc. (NASDAQ:RNA) was mulling over the offer, although the talks could still collapse as other companies have emerged with separate takeover offers. Late last month, Avidity Biosciences, Inc. (NASDAQ:RNA) secured a Breakthrough Therapy designation from the Food and Drug Administration for its del-zota treatment for Duchenne muscular dystrophy (DMD) in patients with DMD44. DMD is a rare genetic condition characterized by progressive muscle damage and weakness due to the loss of dystrophin protein that typically starts at a young age. Del-zota, on the other hand, was designed to deliver phosphorodiamidate morpholino oligomers (PMOs) to skeletal muscle and heart tissue to specifically skip exon 44 of the dystrophin gene and enable production of near-full length dystrophin. While we acknowledge the potential of RNA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the .
Forbes
35 minutes ago
- Forbes
Despite USAID Cuts, Global Health Innovations Offer Glimmers Of Hope
Although the Rescissions Act of 2025, signed into law by President Donald Trump on July 24, retracts approximately $8 billion of funding from the U.S. Agency for International Development, innovations from pharmaceutical companies like Gilead Sciences and Novartis are partnering with nonprofits in order to continue changing lives, even if on a more limited scale. From breakthrough medicines to AI-powered tools, here are some of the next wave solutions that could accelerate the fight against preventable diseases. While it seldom makes headlines, AIDS is still a deadly crisis in many parts of the world. Roughly every minute someone dies of AIDS-related causes. Today, more people live with HIV than there are people in California. And by the time you're done reading this piece, 10 people will have acquired the virus. One of the best ways to combat AIDS is to prevent new infections in the first place. If you achieve that, you lower the transmission rates and stop it from spreading. That's why the new long-acting injectable medicine lenacapavir from Gilead Sciences is so promising The Promise Of Lenacapavir Earlier this year, the Food and Drug Administration approved the medicine for pre-exposure prophylaxis to reduce the risk of adults and adolescents acquiring HIV. Lenacapavir offers individuals protection against HIV for up to six months. Previously, those who were at-risk of acquiring HIV relied on daily PrEP pills that often carried privacy, stigma, and adherence challenges. The medicine's real potential is in places like Sub-Saharan Africa where two-thirds of all new HIV infections originate. Earlier this month, Gilead Sciences and the Global Fund to Fight AIDS, TB and Malaria (which my company donates money to) announced a partnership that will supply the long-acting prevention medicine to low-income countries. Under the agreement, Gilead Sciences will supply the Global Fund enough doses to reach up to 2 million people over three years. 'This is not just a scientific breakthrough — it's a turning point for HIV/AIDS,' Peter Sands, Executive Director of the Global Fund, said in a statement. 'For the first time, we have a tool that can fundamentally change the trajectory of the HIV epidemic — but only if we get it to the people who need it most.' When (RED), the organization that I lead, first met Concillia, she was on the brink of death. She was living with HIV, but wasn't receiving treatment. She weighed under 100 pounds and could barely feed herself, let alone look after her young daughter. Access, stigma, and a lack of education kept her from the life-saving medicine she desperately needed. Then Concillia was connected to a support group of other people living with HIV and began taking antiretroviral medicine. In just 90 days, she was 'resurrected' from death's door. Full of hope and purpose, she soon gave birth to an HIV-free daughter and became a healthcare worker in Lusaka, Zambia to help women just like her. She's living proof that innovation, combined with access, saves lives. When antiretroviral drugs first came on the market, they took years to reach Africa. Millions of people died and many more like Concillia suffered while injustice denied them access to life-saving treatment. Now, low and middle-income countries will have access to this medicine in a timeline that's similar to wealthy countries. It's a massive win for equity and a sign that things are changing for the better. High Hopes For Coartem Baby As Africa prepared for peak malaria season this year, thousands of life-saving bed nets were collecting dust in warehouses across Kenya and Ghana. The nets had already been purchased, but the Trump administration's dismantling of USAID prevented them from being distributed. Malaria is another underreported health crisis that claims a life nearly every minute. Most of the victims are children under the age of five. Symptoms progress quickly and the disease prey's off developing and weakened immune systems. Newborns and small infants have an especially difficult time metabolizing malaria medicine, making it harder for doctors to determine appropriate dosages, which can lead to treatment delays. For the first time, a medicine that's designed specifically to treat newborns and infants with malaria has been approved. Coartem Baby, which is produced by Novartis, can now be used on infants weighing less than roughly 10 lbs. The medicine, which received the green light from Switzerland's therapeutic products regulator is expected to be approved soon in eight African countries — Burkina Faso, Côte d'Ivoire, Kenya, Malawi, Mozambique, Tanzania, Uganda, and Nigeria, which has the highest total annual malaria deaths of any country. The treatment is expected to be sold at a not-for-profit price, making it accessible to more people. 'When there is a medical need that we can address through the science and technologies that we have, we see that as a call to action,' Lutz Hegemann, president of global health at Novartis, told Semafor. The AI Drug Revolution It often costs over $1 billion to bring a new drug to market. Imagine the time and money artificial intelligence could save by predicting a drug's success with near-perfect accuracy. That's exactly what the team at Alphabet's Ismorphic Labs is working on. The company, which was founded by Nobel Prize winner Demis Hassabis, is leveraging artificial intelligence to develop new cancer drugs. Using AlphaFold, a program that predicts protein structures, the company is now able to model how these structures will interact with other molecules. Last year, Ismorphic Labs signed research deals with Novartis and Eli Lilly, and this spring the company raised an additional $600 million in its first-ever external funding round. 'One day we hope to be able to say — well, here's a disease, and then click a button and out pops the design for a drug to address that disease. All powered by these amazing AI tools,' Ismorphic Labs President Colin Murdoch recently told Fortune. The company is not alone. Others like Insilico, Recursion, and Xaira Therapeutics are all working on leveraging AI to accelerate drug discovery and bring new tools to market faster and cheaper. These companies have the potential to help create a future where all preventable and treatable diseases are exactly that — preventable and treatable. But only if these innovations reach people like Concillia. Global experts warn that equity, not just evolution, is needed to ensure new developments reach everyone, everywhere. 'The very last thing that we want to see happen as part of this leap forward with technology is the propagation or amplification of inequities and biases in the social fabric of countries around the world,' Alain Labrique, the WHO's director for digital health and innovation recently warned. Disclosure: My company RED is focused on the global fight to reduce the impact of AIDs and we donate to the Global Fund.
Medscape
37 minutes ago
- Medscape
GMC: Burnout Drops, But Doctors Still Eyeing Exit
Doctors in the UK reported ' marginal, but clear' improvements in wellbeing in 2024, according to the General Medical Council (GMC). Its latest report found that overall satisfaction had risen, burnout risk had dropped, and workloads had eased slightly. However, almost one in five (19%) said they were considering leaving the UK to work abroad – a figure largely unchanged from 18% in 2022 and 20% in 2023. Career Stagnation a Major Concern A third of doctors said they were unable to progress in their education, training, or careers in the way they wanted. The GMC warned that heavy workloads, competition for posts, and lack of senior support for development were harming doctors' career prospects. The report found a clear link between career control and their overall wellbeing. Among doctors who felt able to progress as they wished, 81% reported job satisfaction and 59% were at very low risk of burnout. In contrast, only 33% of those lacking this sense of control were satisfied, and just 18% were at very low risk of burnout. GMC chief executive Charlie Massey said: 'Like any profession, doctors who are disillusioned with their careers will start looking elsewhere." Growing Interest in Overseas Work The report, based on responses from 4697 doctors around the UK, showed that 43% had looked into opportunities abroad. The top reason for considering emigration was the perception that doctors are 'treated better' overseas. Pay was the second most common reason. Some 15% had taken 'hard steps' towards leaving UK practice, such as applying for roles or contacting recruiters. 'We must be alive to the ongoing risks to retention of doctors and the impact of losing talented staff,' the report warned. 'This could threaten Government ambitions to reduce waiting times and deliver better care to patients.' GPs Under Greatest Strain The findings highlighted notable differences between specialties, with general practitioners facing particularly high levels of pressure. GPs were 50% more likely to be struggling compared with all doctors (44% versus 29%). Nearly half (46%) said they were dissatisfied, compared with 33% of all doctors. In addition, 61% of GPs said they found it difficult to provide adequate patient care at least once a week, compared with 40% of all doctors. Burnout Down, Stress Leave Up The proportion of doctors at high risk of burnout dropped from 25% in 2022 to 18% in 2024. However, almost a quarter (23%) took a leave of absence due to stress in 2024 – nearly double the 12% reported in 2019. Although 59% of doctors were satisfied with their day-to-day work in 2024 — up from 53% in 2023 — this remained lower than the 2019 figure of 63%. 'Without action, ambitions to move more patient care from hospitals to communities may well be thwarted,' the GMC warned. Patient Safety Still at Risk In 2024, 40% of doctors said they had seen patient safety being compromised – a figure broadly in line with previous years. The same proportion reported struggling to provide sufficient care weekly – slightly down from 43% in 2023 but still higher than the 34% in the pre-pandemic year of 2019. Inadequate staffing remained the most frequently reported barrier to care, cited by 72% of doctors. Regional Variations Doctors in England, Scotland, and Wales generally reported workplace experiences in line with the UK average. However, in Northern Ireland, responses were notably more negative. There, 26% of doctors were at high risk of burnout compared with an 18% UK average. More than half (54%) said they struggled to provide patient care at least once a week, compared with an average of 40% across the UK as a whole. 'Doctors need to be satisfied, supported, and see a hopeful future for themselves, or we may risk losing their talent and expertise altogether,' warned Massey. Reaction to the Report Commenting on the GMC report, Billy Palmer, senior fellow at the Nuffield Trust think tank, said: 'Pay and industrial action have been a lightning rod for dissatisfaction among doctors, but this survey puts a spotlight on the wider difficulties facing the medical profession. Job guarantees, better rotas and placements, and protection of training time all need to be on the table.' Daniel Elkeles, chief executive of NHS Providers, called for the report's findings to be taken seriously by the NHS. 'It is encouraging to see 'green shoots' emerging, including improvements in doctors' workplace experiences for the second year in a row, and a reduction in burnout risk,' he said. 'But more needs to be done to get back to where we were before the pandemic.'
